Korro Bio, Inc. (KRRO) research
Korro Bio, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.83
- As of
Korro Bio, Inc. (KRRO): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-19.
As of . Source: SEC EDGAR filings for KRRO. Method and limitations.
Share the KRRO intelligence card
See KRRO live in the terminal
Track KRRO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live KRRO terminal, freeActive signals for KRRO
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +86% to KRRO (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 86% of KRRO (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 75% of KRRO (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 96% of KRRO (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in KRRO
FREE, NO ACCOUNT
Every signal on KRRO, as it fires
You are seeing 5 of 24 signals recorded on KRRO since 2026-06-09.
The five above all landed on 2026-09-06. The other 19 were recorded on 4 other days. 20 of the 24 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KRRO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 500946108 · 2026Q2 | $2.3M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 500946108 · 2026Q2 | $1.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 500946108 · 2026Q2 | $1.5M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 500946108 · 2026Q2 | $532K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 500946108 · 2026Q2 | $451K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KRRO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
KRRO against its peers
KRRO's operating margin of -1906.4% ranks in the 35th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2025-12-31.
| Metric | KRRO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 6.4M USD | 2.0M USD | 54 | 11 |
| Operating margin | -1906.4% | -1324.4% | 35 | 9 |
| Net margin | -1834.5% | -1327.4% | 45 | 9 |
| Return on equity | -228.0% | -87.9% | 19 | 17 |
Peers (22): IMUX, CRBP, TNYA, MOLN, NRXP, CLLS, SPRB, CRBU, ARMP, HURA, ENGN, NMRA, MENS, INO, UNCY, HUMA, LENZ, MDWD, COYA, MNOV, OKUR, PMN. Left out: OTLK (no annual filing), CNXU (no annual filing), RNA (no annual filing). Fiscal periods ending between 2025-10-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (KRRO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more KRRO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to KRROand get the insider, 13F, options, and confluence read in one view.